VIRGINIA RETIREMENT SYSTEMS ET Al Acquires 679,000 Shares of Bristol Myers Squibb Company $BMY

VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 43.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,234,496 shares of the biopharmaceutical company’s stock after purchasing an additional 679,000 shares during the quarter. Bristol Myers Squibb accounts for approximately 0.7% of VIRGINIA RETIREMENT SYSTEMS ET Al’s investment portfolio, making the stock its 29th largest holding. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Bristol Myers Squibb were worth $100,776,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Trifecta Capital Advisors LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. increased its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the period. REAP Financial Group LLC raised its stake in shares of Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 428 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC boosted its holdings in shares of Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 231 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $54.22 on Wednesday. The stock’s 50-day moving average is $49.23 and its 200 day moving average is $47.39. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The company has a market cap of $110.38 billion, a P/E ratio of 18.32, a PEG ratio of 8.28 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same period in the prior year, the firm posted $1.80 earnings per share. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.6%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s payout ratio is 83.78%.

Analyst Ratings Changes

Several research analysts have commented on the company. Citigroup reduced their price objective on Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating on the stock in a report on Monday, November 17th. Scotiabank reissued a “sector perform” rating and set a $53.00 price target (up previously from $45.00) on shares of Bristol Myers Squibb in a research report on Thursday, December 4th. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a report on Wednesday, December 3rd. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Finally, Guggenheim reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Tuesday, December 23rd. Six equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $54.62.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.